Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors IVERIC bio
  • Most Recent Events

    • 31 Oct 2016 Primary endpoint has been met. (Mean change in visual acuity from baseline at the Week 24 visit), as per OphthoTech Corporation media release.
    • 31 Oct 2016 Results published in the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.
    • 31 Oct 2016 Results from this trial published online in Ophthalmology, the journal of the American Academy of Ophthalmology, as per OphthoTech Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top